ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Intestinal-targeted medicine-food homology ACE-inhibitory peptide microcapsules ameliorate hypertension in an L-NAME-induced gestational rat model via renin-angiotensin system modulation.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
To develop intestinal-targeted microcapsules combining a medicine-food homology (MFH) complex with the ACE-inhibitory peptide IPP to enhance stability, achieve controlled release, and improve anti-hypertensive efficacy in an L-NAME-induced gestational hypertension rat model. Formulations were optimized by adjusting the complex-to-ACEIP ratio. Encapsulation efficiency, morphology, stability, and in vitro digestion were evaluated. Anti-hypertensive effects were assessed in L-NAME-treated pregnant rats by monitoring blood pressure, urinary protein, and renin-angiotensin system (RAS) biomarkers. The optimal 1:2 ratio showed the highest ACE-inhibitory activity. Spray-dried microcapsules reached 63.37% encapsulation efficiency, uniform morphology, and improved gastrointestinal stability. In vitro digestion showed intestinal-preferential release. In vivo, microcapsules significantly reduced L-NAME-induced hypertension and proteinuria, lowered angiotensin II, decreased ACE expression, and increased ACE2 levels. These microcapsules demonstrate enhanced stability, intestinal targeting, and strong RAS-modulating activity, effectively improving L-NAME-induced pregnancy hypertension and showing potential as a safe functional food ingredient for gestational hypertension management.
Indexed as
Identifiers
41417219What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.